RETIREMENT: Should You Take Social Security ASAP?Shares of small biotech 89bio (ETNB) nearly doubled Thursday after Roche (RHHBY) agreed to buy the MASH drug developer in a deal worth up to $3.5 billion.89bio is working on a treatment for MASH, or metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease often associated with obesity, type 2 diabetes and high blood pressure. Its drug, pegozafermin, mimics a protein that helps regulate glucose and lipid metabolism.The acquisition underl ...